Sorrento Announced Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter
On Jul. 20, 2020, Sorrento announced that its partner Mabpharm had received approval of its New Drug Application…
-
-
ViralClear partnered with Albany Molecular on manufacture of merimepodib API development for potential treatment of COVID-19
On Jul. 9, 2020, BioSig Technologies and its subsidiary, ViralClear Pharma announced that it is partnering with Albany…
-
Fujifilm partnered with Dr. Reddy’s and Global Response Aid for deployment of a COVID-19 treatment drug outside of Japan
On Jul. 1, 2020, FUJIFILM announced a partnership with Dr. Reddy’s Laboratories, a global pharmaceutical company headquartered in…
-
Merck and Ridgeback Bio announced closing of collaboration and licensing transaction
On Jul. 1, 2020, Merck and and and Ridgeback Biotherapeutics announced that the U.S. Federal Trade Commission (FTC)…
-
Takeda received FDA approval to manufacture ENTYVIO (vedolizumab) drug substance at Brooklyn Park, Minnesota facility
On Jun. 23, 2020, Takeda Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) had approved the…
-
Catalent partnered with ViralClear Pharmaceuticals on potential treatment for COVID-19
On Jun. 22, 2020, Catalent announced that it is partnering with ViralClear Pharmaceuticals, a subsidiary of BioSig Technologies,…
-
Biotechnology | Clinical Research | COVID-19 | Diagnostics | Infectious Disease | Pharmaceutical | Vaccine
GSK COVID-19 vaccine development collaboration with Clover Biopharmaceuticals began clinical trials
On Jun. 19, 2020, GSK announced that a scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19…
-
Biotechnology | FDA | Medicine | Oncology | Pharmaceutical | Radiology | Therapeutics
FDA approved Bristol-Myers’ Opdivo’ (nivolumab) for treatment of patients with advanced esophageal squamous cell carcinoma
On Jun. 11, 2020, Bristol-Myers Squibb announced that Opdivo ® (nivolumab) was approved by the U.S. Food and…
-
Agriculture | Biology | Cardiology | Disease | NIH | Pharmaceutical | U.S. Congress | USDA
NIH released strategic plan to accelerate nutrition research over next 10 years
On May 27, 2020, the National Institutes of Health (NIH) Nutrition Research Task Force (NRTF), armed with insights…
-
University of Alberta researchers launched a joint effort with US-based Tonix Pharma to develop and test a vaccine against COVID-19
On May 13, 2020, University of Alberta (UA) researchers launched a joint effort with U.S.-based Tonix Pharmaceuticals to…
-
Combing through old drugs to find new ones for COVID-19
On May 12, 2020, the Broad Institute’s Drug Repurposing Hub announced that it had opened its repository of…
-
U of Alberta pharmaceutical institute leads effort to fill looming hospital drug shortage during fight against COVID-19
On May 11, 2020, a University of Alberta-initiated institute leads province wide effort to fill the looming shortage…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Pharmaceutical | Therapeutics | Vaccine
USPTO announced COVID-19 Prioritized Examination Pilot Program for small and micro entities
On May 8, 2020, the U.S. Patent and Trademark Office (USPTO) announced a new COVID-19 Prioritized Examination Pilot…
-
The CoVIg-19 Plasma Alliance was established
On May 8, 2020, the CoVIg-19 Plasma Alliance was announced, an unprecedented partnership of the world’s leading plasma…
-
AbbVie completed acquisition of Allergan for nearly $62 billion
On May 8, 2020, AbbVie announced it had completed its acquisition of Allergan following receipt of regulatory approval…
-
Entos Pharma partnered with Precision NanoSystems to enable scalable GMP manufacturing of Fusogenix DNA COVID-19 vaccine
On May 7, 2020, Entos Pharmaceuticals announced a partnership with Precision NanoSystems, Inc., (PNI), a global leader in…
-
Laurent Pharmaceuticals received Health Canada’s approval to initiate COVID-19 clinical trial
On May 6, 2020, Laurent Pharmaceuticals announced that it has obtained the approval from Health Canada to initiate…
-
Mesoblast announced first patients dosed in phase 2/3 trial for COVID-19 ARDS
On May 6, 2020, Mesoblast announced that the first patients were dosed in the 300-patient randomized placebo-controlled Phase…
-
Biotechnology | COVID-19 | Diagnostics | Medical Device | Non-Profit Research | Pharmaceutical | Therapeutics
USPTO launched platform to facilitate connections between patent holders and potential licensees in key technologies
On May 4, 2020, the U.S. Patent and Trademark Office (USPTO) unveiled a new web-based intellectual property marketplace…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Non-Profit Research | Pharmaceutical | Therapeutics
Government of Canada Investing in global race to find a treatment for COVID-19
On May 3, 2020, the Government of Canada announced it was investing in projects that support the global…
-
Mesoblast began enrollment in phase 2/3 clinical trial of remestemcel-L in 300 patients with acute respiratory distress syndrome
On Apr. 30, 2020, Mesoblast announced a Phase 2/3 randomized, placebo-controlled trial to rigorously confirm whether its allogeneic…
-
Mateon announced peer reviewed publication on its R&D effort against COVID-19
On Apr. 30, 2020, Mateon Therapeutics report several peer-reviewed publications derived from its R&D effort against COVID-19. Published April…
-
Entos Pharmaceuticals partnered with EpiVax to develop a pan-Coronavirus DNA vaccine
On Apr. 28, 2020, Entos Pharmaceuticals announced a collaboration with EpiVax, a world leading informatics and immunology biotechnology…
-
Phase 3 trial of Libtayo (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival
On Apr. 27, 2020, Regeneron and Sanofi announced the primary endpoint of overall survival was met in a…
-
Mesoblast reported 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory distress syndrome
On Apr. 24, 2020, Mesoblast announced an 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory…
-
Emergent BioSolutions signed agreement to be U.S. manufacturing partner for Johnson & Johnson’s lead vaccine candidate for COVID-19
On Apr. 23, 2020, Emergent BioSolutions announced an agreement whereby Emergent will deploy its contract development and manufacturing…
-
Cocrystal Pharma expanded exclusive license agreement with Kansas State University Research Foundation to new Coronavirus antiviral compound
On Apr. 22, 2020, Cocrystal Pharma announced it has expanded its previously announced license agreement with Kansas State…
-
Biology | Diagnostics | Infectious Disease | Life Science History | Medicine | Pharmaceutical | Radiology | Therapeutics | U.S. Congress | Vaccine
The US Veterans Affairs established the department’s first history office
On Apr. 10, 2020, the U.S. Department of Veterans Affairs (VA) established the VA History Office (VAHO) to…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Medicine | Pharmaceutical | Therapeutics
Data on 53 patients treated with investigational antiviral remdesivir through Compassionate Use Program published in NEJM
On Apr. 10, 2020, Gilead Sciences announced results from a cohort analysis of 53 patients hospitalized with severe…
-
Biotechnology | COVID-19 | Infectious Disease | Influenza | Medicine | Pharmaceutical | Therapeutics
Fujifilm announced the start of a phase II clinical trial of its influenza antiviral drug ‘Avigan’ Tablet for COVID-19 patients in the U.S.
On Apr. 9, 2020, FUJIFILM announced initiation of a U.S. phase II clinical trial to evaluate the safety…
